CP and COVID-19: Previously, most nonclinical studies of preventive or therapeutic COVID‐19 drugs focused on monoclonal antibodies or chemical drugs.[37, 38, 39, 40] Few studies have examined the efficacy of CP or anti‐SARS‐CoV‐2 hyperimmune globulin in vivo.